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1. Introduction 
 Permanent or transient damage with serious implications 
on adjacent organs and systems may be due to tissue hypoxia 
reoxygenation (HR). The use of U-74389G in HR has been a challenge 
for many years. However, although the progress was significant, 
several practical questions have not been clarified yet. They include: 
a) how potent U-74389G should be b) when should it be 
administered and c) at what optimal dose U-74389G should be 
administered. The promising effect of U-74389G in tissue protection 
has been noted in several HR studies. U-74389G or also known as 21-
[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-pregna-
1,4,9(11)-triene-3,20-dione maleate salt is an antioxidant which 
prevents both arachidonic acid-induced and iron-dependent lipid 
peroxidation[1]. It protects against HR injury in animal organs such 
as heart, liver and kidney models. These membrane-associating 
antioxidants are particularly effective in preventing permeability 
changes in brain microvascular endothelial cells monolayers[2]. A 
meta-analysis of 24 published seric variables, coming from the same 
experimental setting, tried to provide a numeric evaluation of the U-
74389G efficacy at the same endpoints (Table 1).  
The aim of this experimental study was to evaluate the 
effect of U-74389G in a rat model of HR using blood mean 
corpuscular volume (MCV) levels. 
 
2. Materials and methods 
2.1 Animal preparation 
This basic experimental research was licensed by 
Veterinary Address of East Attiki Prefecture under 3693/12-11- 
2010 & 14/10-1-2012 decisions. All consumables, equipment and 
substances used, were a grant of Experimental Research Centre of 
ELPEN Pharmaceuticals Co. Inc. S.A. at Pikermi, Attiki. Accepted 
standards of humane animal care were adopted for Albino female 
Wistar rats. 7 days pre-experimental normal housing included ad 
libitum diet in laboratory. Post-experimental awakening and 
preservation of animals was not permitted even if euthanasia was 
required. Rats were randomly delivered to four experimental groups 
by 10 animals in each one, using following protocols of HR: Hypoxia 
for 45 min followed by reoxygenation for 60 min (group A). Hypoxia 
for 45 min followed by reoxygenation for 120 min (group B). Hypoxia 
for 45 min followed by immediate U-74389G intravenous (IV) 
administration and reoxygenation for 60 min (group C). Hypoxia for 
45 min followed by immediate U-74389G IV administration and 
reoxygenation for 120 min (group D). The molecule U-74389G 
dosage was 10 mg/Kg body weight of animals. 
Prenarcosis preceded of continuous intra-experimental 
general anesthesia, oxygen supply, electrocardiogram and 
acidometry[3-6]. Hypoxia was caused by laparotomic clamping 
inferior aorta over renal arteries with forceps for 45 min. 
Reoxygenation was induced by removing the clamp and 
reestablishment the inferior aorta patency. After exclusion of blood 
flow, the protocol of HR was applied, as described above for each 
experimental group. U-74389G was administered at the time of 
reoxygenation through inferior vena cava catheter. The MCV levels 
were determined at 60th min of reoxygenation (for A and C groups) 
and at 120th min of reoxygenation (for B and D groups). Fourty 
female Wistar albino rats were used (mean weight 231.875 g 
[standard deviation (SD): 36.59703 g], with minimum weight 165 g 
and maximum weight 320 g. Rats' weight could be potentially a 
confusing factor, e.g. more obese rats to have higher MCV levels. This 
assumption was also investigated. 
2.2 Control groups 
20 control rats of mean weight 252.5 g [SD: 39.31988 g] 
experienced hypoxia for 45 min followed by reoxygenation.  
Group A: Reoxygenation which lasted 60 min concerned 10 controls 
rats of mean weight 243 g [SD: 45.77724 g] and mean MCV 59.17 fl 
[SD: 2.730914 fl] (Table 2).     
Group B: Reoxygenation which lasted 120 min concerned 10 
controls rats of mean weight 262 g [SD: 31.10913 g] and mean MCV 
58.81 fl [SD: 1.397975 fl] (Table 2).     
Lazaroid (L) group: 20 rats of mean weight 211.25 g [SD: 17.53755 
g] experienced hypoxia for 45 min followed by reoxygenation in the 
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beginning of which 10 mg U-74389G /kg body weight were IV 
administered.  
Group C: Reoxygenation which lasted 60 min concerned 10 L rats of 
mean weight 212.5 g [SD: 17.83411 g] and mean MCV 61.61 fl [SD: 
1.67561 fl] (Table 2).     
Group D: Reoxygenation which lasted 120 min concerned 10 L rats 
of mean weight 210 g [SD: 18.10463 g] and mean MCV 61.22 fl [SD: 
1.487578 fl] (Table 2).     
2.3 Statistical analysis 
Every weight and MCV level group was compared with 
each other by statistical standard t-tests (Table 3). Any significant 
difference among MCV levels, was investigated whether owed in 
probable significant weight correlations. The generalized linear 
models (glm) with dependant variable the MCV levels were applied. 
The 3 independent variables were the U-74389G or no drug, the 
reoxygenation time and both variables in combination. Inserting the 
rats’ weight also as an independent variable at glm analysis, a very 
significant relation resulted in with MCV levels (p=0.0000), so as to 
further investigation was needed. The predicted MCV values were 
calculated for every rat and are depicted at table 5. Every predicted 
MCV level group was compared with each other by statistical 
standard t-tests (Table 3). The glm with dependant variable the 
predicted MCV levels were iterated. The 3 independent variables 
were again the U-74389G or no drug, the reoxygenation time and 
both variables in combination.   
3. Results 
The first glm resulted in: U-74389G administration 
significantly increased the MCV levels by 2.425 fl [1.235015 fl - 
3.614985 fl] (p= 0.0002). This finding was in accordance with the 
results of standard t-test (p= 0.0026). Reoxygenation time non-
significantly increased the MCV levels by 0.3749996 fl [-1.80157 fl - 
1.051571 fl] (p= 0.5977), also in accordance with standard t-test (p= 
0.1226). However, U-74389G administration and reoxygenation time 
together significantly increased the MCV levels by 1.251818 fl 
[0.492508 fl - 2.011128 fl] (p= 0.0019). Reviewing the above and 
table 3, table 4 sums up concerning the increasing influence of U-
74389G in connection with reoxygenation time. The second glm 
resulted in: U-74389G administration significantly increased the 
predicted MCV levels by 1.735536 fl [0.9155627 fl - 2.55551 fl] (p= 
0.0001). This finding was in accordance with the results of standard 
t-test (p= 0.0002). Reoxygenation time non-significantly increased 
the MCV levels by 0.3471077 fl [-1.339179 fl - 0.6449639 fl] (p= 
0.4831), also in accordance with standard t-test (p= 0.3375). 
However, U-74389G administration and reoxygenation time together 
significantly increased the MCV levels by 0.9657804 fl [0.4538955 fl - 
1.477665 fl] (p= 0.0005). Reviewing the above and table 6, the tables 
7 and 8 sum up; concerning the increasing influence of U-74389G in 
connection with reoxygenation time. 
 
Table 1:  The U-74389G influence (±SD) on the levels of some seric variables3 concerning reperfusion (rep) time 
 
Variable 1h rep p-value 1.5h rep p-value 2h rep p-value 
interaction of U-
74389G and rep 
p-
value 
WBCC +22.99%±12.45% 0.0914 +30.85%±11.14% 0.0045 +38.70%±17.39% 0.0185 +23.45%±6.28% 0.0004 
RBCC   +1.39%±0.71% 0.7161 +0.64%±0.32% 0.8106 -0.10%±0.05% 0.9762 +1.05%±0.53% 0.4911 
Hematocrit +5.58%±3% 0.0852 +4.73%±2.25% 0.0435 +3.89±3.44% 0.2608 +3.16%±1.33% 0.0196 
Hemoglobin +5.2%±2.8% 0.0925 +3.9%±2.1% 0.0604 +2.7%±3.2% 0.3544 +2.5%±1.3% 0.0423 
MCH +1.77%±0.96% 0.0663 +2.40%±0.57% 0.0001 +3.03%+0.71% 0.0003 1.33%+0.36% 0.0005 
MCHC2 -0.5%±0.74% 0.4820 -0.95%±0.63% 0.1124 -1.4%±1.12% 0.1603 -0.69%±0.37% 0.0655 
RbcDW -6.13%±3.73% 0.0667 -4.96%±2.27% 0.0175 -3.80%±3.07% 0.1383 -2.54%±1.39% 0.679 
Platelet count2 -17.79%±9.40% 0.0647 -12.83%±5.79% 0.0303 -7.88%±7.83% 0.2939 -6.12%±3.58% 0.0857 
Platelet-crit +3.80%±9.87% 0.6373 +9.23%±6.29% 0.1064 +14.66%±9.03% 0.0833 +6.72%±3.73% 0.0712 
PDW +1.1%±0.88% 0.2368 +1.79%±0.76% 0.0314 +2.49%±1.33% 0.0807 +0.96%±0.46% 0.0396 
Glucose -6.41%±3.50% 0.0663 -8.57%±2.06% 0.0001 -10.74%±2.52% 0.0003 -4.76%±1.28% 0.0005 
Creatinine3 -15.96%±8.71% 0.0663 -21.02%±5.06% 0.0001 -26.09%±6.12% 0.0003 -11.69%±3.16% 0.0005 
Uric acid4 +20.86%±14.44% 0.1614 +15.43%±9.10% 0.0960 +10%±12.11% 0.3946 +4.78%±5.64% 0.3873 
Total protein                -5.48%±2.99% 0.0663 -7.34%±1.76% 0.0000 -9.20%±2.16% 0.0000 -4.08%±1.10% 0.0000 
γGT +19.35%±18.58% 0.2362 +6.82%±14.89% 0.6442 -5.71%±20.10% 0.7809 +1.23%±9% 0.8877 
ALP  +22.66%±12.37% 0.0663 +31.91%±7.69% 0.0001 +41.16%±9.65% 0.0003 +17.75%±4.79% 0.0005 
ACP -112.54%±20.95% 0.0006 -128.45%+14.84% 0.0000 -144.36%±21.62% 0.0000 -74.45%±9.63% 0.0000 
CPK +54.32%±13.75% 0.0012 +35.34%±17.20% 0.0260 +16.37%±30.24% 0.4951 +18.52%±9.44% 0.0770 
Sodium   +1.22%±0.66% 0.0707 +0.17%±0.61% 0.7714 -0.87%±1.03% 0.3995 -0.32%±0.36% 0.3693 
Chloride   -0.58%±0.77% 0.4533 -0.97%±0.53% 0.0879 -1.36%±0.76% 0.1113 -0.75%±0.38% 0.0159 
Calcium    0%±1.75% 1 -0.14%±1.10% 0.8782 -0.28%±1.54% 0.8492 +0.14%±0.64% 0.8245 
Phosphorus   -2.23%±5.51% 0.7966 -1.61%±3.32% 0.5789 -1%±4.48% 0.8129 -1.09%±2% 0.5771 
Magnesium +1.33%±3.59% 0.7033 -0.28%±2.75% 0.9171 -1.90%±5.28% 0.7161 +0.36%±4.58% 0.8228 
Mean -0.26%±28.78% 0.2707 -1.90%±30.75% 0.2268 -3.55%±33.95% 0.3011 -1.06%±17.88% 0.2107 
 
 
 
 
C. Τsompos et al / The effect of erythropoietin on creatine kinase MB levels during ischemia reperfusion injury in rats 
 
© ASD Publisher All rights reserved.                                                                                                                                                                                                         56 
Table 2: Weight, MCV levels and Std. Dev. of groups 
Groups Variable Mean Std. Dev    
Α Weight 243 g 45.77724 g 
MCV 59.17 fl 2.730914 fl 
B Weight 262 g 31.10913 g 
MCV 58.81 fl 1.397975 fl 
C Weight 212.5 g 17.83411 g 
MCV 61.61 fl 1.67561 fl 
D Weight 210 g 18.10463 g 
MCV 61.22 fl 1.487578 fl 
 
Table 3: Statistical significance of mean values differences for 
groups (DG) after statistical paired t test application 
DG Variable Difference p-value    
Α-Β                    Weight -19 g 0.2423 
MCV 0.3599998 fl 0.5275 
Α-C Weight 30.5 g 0.0674 
MCV -2.44 fl 0.0777 
Α-D                   Weight 33 g 0.0574 
MCV -2.05 fl 0.0916 
Β-C Weight 49.5 g 0.0019 
MCV -2.799999 fl 0.0078 
Β-D Weight 52 g 0.0004 
MCV -2.41 fl 0.0105 
C-D Weight 2.5 g 0.7043 
MCV 0.3899994 fl 0.4655 
 
Table 4: The increasing influence of U-74389G in connection 
with reoxygenation time 
Increase 95% c. in. 
Reperfusion 
time 
p-values 
t-test glm   
2.44 fl 0.3113641 
fl - 
4.568635 fl 
1h 0.0777   0.0270 
2.425 fl 1.235015 fl 
- 3.614985 
fl 
1.5h 0.0026                              0.0002
2.41 fl 1.05377 fl - 
3.76623 fl 
2h 0.0105    0.0015 
0.3749996 
fl 
-1.80157 fl - 
1.051571 fl 
reoxygenation 
time 
0.5977   0.1226 
1.251818 
fl                 
0.492508 fl 
- 2.011128 
fl 
interaction  0.0019 
 
Table 5: Predicted MCV levels and Std. Dev. of groups corrected 
for weights 
Group Mean Std. Dev. 
A 59.73443 fl 1.926011 fl 
B 58.93503 fl 1.308871 fl 
C 61.01768 fl 0.7503465 fl 
D 61.12286 fl 0.7617265 fl 
 
Table 6: Statistical significance of predicted MCV values 
differences for groups (DG) corrected for weights after 
statistical paired t test application 
DG Difference   p-value    
A-B 0.7993977 fl 0.2423   
A-C -1.283247  fl                                       0.0674        
Α-D -1.388429 fl                                       0.0574    
Β-C -2.082644 fl    0.0019 
Β-D -2.187827 fl                                        0.0004      
C-D -0.1051826 fl                                        0.7043
 
Table 7: The predicted increasing influence of U-74389G in 
connection with reoxygenation time 
Increase 95% c. in. 
Reperfusion 
time 
p-values 
t-test Glm 
1.283247  
fl          
-0.090014 fl - 
2.656507 fl 
1h 0.0674   0.0653 
1.735537 
fl 
0.9155627 fl 
- 2.55551 fl 
1.5h                   0.0002    0.0001                            
2.187827 
fl 
1.181713 fl - 
3.19394 fl 
2h 0.0004    0.0002 
0.3471077 
fl 
-1.339179 fl - 
0.6449639 fl 
reoxygenation 
time             
0.4831 0.3375 
0.9657804 
fl 
0.4538955 fl 
- 1.477665 fl 
    interaction                   0.0005     
 
Table 8: The (%) predicted increasing influence of U-74389G in 
connection with reoxygenation time 
Increase ±SD                                  Reperfusion time             p-values   
+2.12% ±1.16% 1h 0.0663 
+2.88% ±0.69% 1.5h 0.0001 
+3.64% ±0.85% 2h 0.0003 
+0.57% ±0.83% reoxygenation time 0.4103 
+1.60% ±0.43% interaction 0.0005 
4. Discussion 
4.1 Hypoxia may influence MCV levels 
 Yildiz et al[7] significantly decreased the blood MCV levels 
(p<0.05) after both testicular torsion rotation and low dose sildenafil 
citrate administration in male Wistar rats. Nemeth et al[8] found 
higher MCV levels daily for one week in early postoperative period 
after hind-limb IR (+ allopurinol) than in sham operated and control 
male rats groups. Berra et al [9] enhanced the MCV levels after 14 
days experimental infection with Trypanosoma cruzi (Chagas' 
disease) than 7 days infected and control rats. Putintsev et al 
revealed [10] increased MCV levels in an exacerbated chronic 
obstructive bronchitis combined with coronary heart disease. 
Mueller et al [11] predicted MCV as an independent factor of severe 
atherosclerosis in the iliac arterial disease (OR = 2.72 for an 
increment of 5 fl) and in the femoral-popliteal arterial disease 
segment (OR = 3.13 for an increment of 5 fl). Higher MCV values were 
contributed to symptomatic peripheral arterial disease (PAD) lumen 
reductions > 75% of the proximal segments in patients compared 
with matched control subjects. Wilke et al[12] diagnosed an 
intestinal leiomyoma that led to chronic anemia and conspicuous 
MCV of 63 fl and furthermore to angina pectoris. Penix et al[13] 
showed an increased MCV value, normalized by vitamin B12 
administration in two ischemic cerebral infarctions 16 years after 
ileal resection for Crohn's disease. Donaldson et al[14] induced 
significant acute decreases in MCV levels, lasting 1-2 days after short-
term falls in temperature. Chen et al[15] decreased the MCV levels 
providing regular transfusions and chelation therapy in 75.6% of 
Diamond Blackfan anemia patients; the 24.4% of which having 
macrocytic anemia unresponsive to corticosteroids.  
This study is the first attempting to relate MCV levels with 
U-74389G administration.  
 
5. Conclusion 
U-74389G administration whether it interacted or not with 
reoxygenation time has significant increasing short – term effect on 
recovery pathophysiology of MCV values.  
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